{"id":535439,"date":"2021-09-08T08:03:03","date_gmt":"2021-09-08T12:03:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/"},"modified":"2021-09-08T08:03:03","modified_gmt":"2021-09-08T12:03:03","slug":"cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/","title":{"rendered":"Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., Sept.  08, 2021  (GLOBE NEWSWIRE) &#8212; Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Company management will present at two upcoming investor conferences.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt;text-align:left\">H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021. On-demand session is available starting at 7:00 a.m. EDT on September 13<sup>th<\/sup>.<\/li>\n<li style=\"margin-bottom:8pt\">Cantor Fitzgerald Virtual Global Healthcare Conference, September 30, 2021 at 2:40 p.m. EDT.<\/li>\n<\/ul>\n<p>The live webcasts can be accessed via the Investors &amp; Media section of the Cyclerion website at https:\/\/ir.cyclerion.com\/news-events\/event-calendar. An archived replay of the events will be available on the site for approximately 90 days following the presentations.<\/p>\n<p>\n        <strong>About Cyclerion Therapeutics<\/strong>\n      <\/p>\n<p>Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion is advancing novel, first-in-class, CNS-penetrant, sGC stimulators that modulate a key node in a fundamental CNS signaling pathway. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases. The most advanced compound, CY6463 has shown rapid improvement in biomarkers associated with cognitive function and is currently in clinical development for Alzheimer&#8217;s Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associated with Schizophrenia (CIAS). Cyclerion is also advancing CY3018, a next generation sGC stimulator.<\/p>\n<p>For more information about Cyclerion, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T7em8dsrQI7QMBU5s6pWj8NVgoNCL6tWdVYS30GNEvyVX8eersSrYXGb7HJ6lY6hqCkD7nZugUGK6G1t3pxmsxkD1bcLytSjTdi4RNh6VQ8=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.cyclerion.com\/<\/a> and follow us on Twitter (@Cyclerion) and LinkedIn (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EUrM4X5hrxB52CGxPpA6hM_v7zGqkGwjDpeULVszaQBnta6Nd8h2T5YYtTgZ8vpsXbkM1BkLI8BnqJxY6bG9a_oA_d3LERC277yc2z0hvvatsLeIYYCyOWS1hh0hEmUuS5s7SRhX4kErxo1qlhHJ4Q==\" rel=\"nofollow noopener\" target=\"_blank\">www.linkedin.com\/company\/cyclerion<\/a>).<\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Carlo Tanzi, Ph.D.<br \/>Kendall Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PPthJDCMX0JWYXzaQki2tOCsXqrCdIeAPdMA90BVzDC0mPXcUrx3CsktarqhyYOvsmNHswWDqHiFK4SlPYTWkgAQxu8qQESJvNHj2kZ1kd8=\" rel=\"nofollow noopener\" target=\"_blank\">ctanzi@kendallir.com<\/a><\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Amanda Sellers<br \/>Verge Scientific Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yAWYBN-_rxOpLjLj3fAzc2uwJXaXs_aF2fXmdi1QQ5Qq_5Dp64rrxGSwcLD4QmlkaUxtvyd00h836UZs6JyIq9FyKm1D5PhcQLlrrl2uRC1lKlN5W2uhNIN3Di3PBxk7\" rel=\"nofollow noopener\" target=\"_blank\">asellers@vergescientific.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTczNSM0MzkzMzQ5IzIxMjUwMjQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjBhYzNjMWItNTQ1Ni00YzNhLWI4YjctYTgwODFiZGNhMjcwLTExMzY1OTU=\/tiny\/Cyclerion-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Company management will present at two upcoming investor conferences. H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021. On-demand session is available starting at 7:00 a.m. EDT on September 13th. Cantor Fitzgerald Virtual Global Healthcare Conference, September 30, 2021 at 2:40 p.m. EDT. The live webcasts can be accessed via the Investors &amp; Media section of the Cyclerion website at https:\/\/ir.cyclerion.com\/news-events\/event-calendar. An archived replay of the events will be available on the site for approximately 90 days following the presentations. About Cyclerion Therapeutics Cyclerion Therapeutics is a clinical-stage biopharmaceutical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-535439","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Company management will present at two upcoming investor conferences. H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021. On-demand session is available starting at 7:00 a.m. EDT on September 13th. Cantor Fitzgerald Virtual Global Healthcare Conference, September 30, 2021 at 2:40 p.m. EDT. The live webcasts can be accessed via the Investors &amp; Media section of the Cyclerion website at https:\/\/ir.cyclerion.com\/news-events\/event-calendar. An archived replay of the events will be available on the site for approximately 90 days following the presentations. About Cyclerion Therapeutics Cyclerion Therapeutics is a clinical-stage biopharmaceutical &hellip; Continue reading &quot;Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-08T12:03:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTczNSM0MzkzMzQ5IzIxMjUwMjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences\",\"datePublished\":\"2021-09-08T12:03:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/\"},\"wordCount\":276,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTczNSM0MzkzMzQ5IzIxMjUwMjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/\",\"name\":\"Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTczNSM0MzkzMzQ5IzIxMjUwMjQ=\",\"datePublished\":\"2021-09-08T12:03:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTczNSM0MzkzMzQ5IzIxMjUwMjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTczNSM0MzkzMzQ5IzIxMjUwMjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Company management will present at two upcoming investor conferences. H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021. On-demand session is available starting at 7:00 a.m. EDT on September 13th. Cantor Fitzgerald Virtual Global Healthcare Conference, September 30, 2021 at 2:40 p.m. EDT. The live webcasts can be accessed via the Investors &amp; Media section of the Cyclerion website at https:\/\/ir.cyclerion.com\/news-events\/event-calendar. An archived replay of the events will be available on the site for approximately 90 days following the presentations. About Cyclerion Therapeutics Cyclerion Therapeutics is a clinical-stage biopharmaceutical &hellip; Continue reading \"Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-08T12:03:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTczNSM0MzkzMzQ5IzIxMjUwMjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences","datePublished":"2021-09-08T12:03:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/"},"wordCount":276,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTczNSM0MzkzMzQ5IzIxMjUwMjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/","name":"Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTczNSM0MzkzMzQ5IzIxMjUwMjQ=","datePublished":"2021-09-08T12:03:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTczNSM0MzkzMzQ5IzIxMjUwMjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTczNSM0MzkzMzQ5IzIxMjUwMjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-to-participate-in-two-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535439","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=535439"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535439\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=535439"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=535439"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=535439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}